MX2022008215A - Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. - Google Patents
Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo.Info
- Publication number
- MX2022008215A MX2022008215A MX2022008215A MX2022008215A MX2022008215A MX 2022008215 A MX2022008215 A MX 2022008215A MX 2022008215 A MX2022008215 A MX 2022008215A MX 2022008215 A MX2022008215 A MX 2022008215A MX 2022008215 A MX2022008215 A MX 2022008215A
- Authority
- MX
- Mexico
- Prior art keywords
- mother
- peptides
- maternal autoantibodies
- potential
- ldh
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 206010003805 Autism Diseases 0.000 title 1
- 208000020706 Autistic disease Diseases 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 230000008774 maternal effect Effects 0.000 abstract 4
- 102100022188 Dihydropyrimidinase-related protein 1 Human genes 0.000 abstract 2
- 102100024426 Dihydropyrimidinase-related protein 2 Human genes 0.000 abstract 2
- 108010012029 Guanine Deaminase Proteins 0.000 abstract 2
- 102000013587 Guanine deaminase Human genes 0.000 abstract 2
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 abstract 2
- 101710140918 Stress-induced-phosphoprotein 1 Proteins 0.000 abstract 2
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 abstract 2
- 102000009266 Y-Box-Binding Protein 1 Human genes 0.000 abstract 2
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- 108010022820 collapsin response mediator protein-1 Proteins 0.000 abstract 2
- 108010022822 collapsin response mediator protein-2 Proteins 0.000 abstract 2
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 abstract 1
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención proporciona péptidos que se unen específicamente a anticuerpos maternos que son generados en la madre o madre potencial contra uno o más antígenos polipeptídicos endógenos seleccionados de lactato deshidrogenasa A (LDH A), lactato deshidrogenasa B (LDH B), fosfoproteína producida por tensión 1 (STPIP1), guanina desaminasa (GDA), proteína de unión de la casilla Y 1(YBX1), proteína mediadora de la respuesta a la colapsina 1 (CRMP1) y proteína mediadora de la respuesta a la colapsina 2 (CRMP2). Los polipéptidos descritos en la presente son útiles para determinar un riesgo de que un descendiente desarrolle un trastorno del espectro de autista (ASD) detectando la presencia de anticuerpos maternos en una muestra biológica de la madre o madre potencial. Los péptidos o mimotopos de los mismos pueden ser administrados también a la madre o madre potencial para bloquear la unión entre los anticuerpos maternos y sus antígenos, neutralizando por los tanto los anticuerpos maternos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185186P | 2015-06-26 | 2015-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008215A true MX2022008215A (es) | 2022-08-04 |
Family
ID=57585879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016329A MX2017016329A (es) | 2015-06-26 | 2016-06-23 | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. |
| MX2022008215A MX2022008215A (es) | 2015-06-26 | 2017-12-14 | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016329A MX2017016329A (es) | 2015-06-26 | 2016-06-23 | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11098082B2 (es) |
| EP (2) | EP3314258B1 (es) |
| JP (1) | JP6873060B2 (es) |
| CN (1) | CN108184330B (es) |
| AU (1) | AU2016281649B2 (es) |
| CA (1) | CA2989882A1 (es) |
| ES (1) | ES2964981T3 (es) |
| HK (1) | HK1254818A1 (es) |
| MX (2) | MX2017016329A (es) |
| WO (1) | WO2016210137A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383360B2 (en) | 2009-08-14 | 2013-02-26 | The Regents Of The University Of California | Methods of diagnosing and treating autism |
| EP3314258B1 (en) | 2015-06-26 | 2023-11-15 | The Regents of the University of California | Antigenic peptides and uses thereof for diagnosing and treating autism |
| AU2020265406A1 (en) * | 2019-05-02 | 2022-01-06 | Université Catholique de Louvain | Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer |
| MX2022005611A (es) * | 2019-11-25 | 2022-07-27 | Univ California | Peptidos antigenicos de enolasa especificos de neuronas para el diagnostico y el tratamiento del autismo. |
| CN113238045B (zh) * | 2021-04-27 | 2021-12-28 | 南方医科大学南方医院 | Crmp2及抗crmp2抗体的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| WO2002046767A2 (en) * | 2000-12-08 | 2002-06-13 | Oxford Glycosciences (Uk) Ltd. | Diagnosis and treatment of alzheimer's disease |
| US20030064411A1 (en) * | 2000-12-08 | 2003-04-03 | Herath Herath Mudiyanselage Athula Chandrasiri | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease |
| CA2449272A1 (en) | 2001-06-08 | 2002-12-19 | Incyte Genomics Inc. | Intracellular signaling molecules |
| ATE517629T1 (de) * | 2001-09-07 | 2011-08-15 | Inst Nat Sante Rech Med | Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP2006524035A (ja) * | 2002-12-26 | 2006-10-26 | シーマインズ リミテッド ライアビリティ カンパニー | 癌の診断、予後診断および治療のための方法および組成物 |
| US7452678B2 (en) | 2003-06-24 | 2008-11-18 | Bristol-Myers Squibb Company | Identification of biomarkers for liver toxicity |
| WO2005007090A2 (en) | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| JP2007512027A (ja) | 2003-11-21 | 2007-05-17 | レビビコア， インコーポレイテッド | トランスジェニック動物の産生における干渉ｒｎａの使用 |
| EP1859266A4 (en) * | 2005-02-24 | 2010-07-28 | Cemines Inc | COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES |
| WO2006121912A2 (en) | 2005-05-05 | 2006-11-16 | The Regents Of The University Of California | Diagnostic methods for the detection of risk of neurodevelopmental disorders |
| US7604948B2 (en) | 2005-05-05 | 2009-10-20 | The Regents Of The University Of California | Biomarkers for diagnosing an autism spectrum disorder |
| GB0524609D0 (en) | 2005-12-02 | 2006-01-11 | Univ Cambridge Tech | Methods of monitoring and diagnosing psychotic disorders and of identifying biomarkers for psychotic disorders |
| GB0602992D0 (en) | 2006-02-15 | 2006-03-29 | Morvus Technology Ltd | Methods, genes and proteins |
| CA2660286A1 (en) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2008070311A2 (en) | 2006-10-20 | 2008-06-12 | Gene Logic, Inc. | Gene expression profiling of parkinson's disease |
| WO2008099972A1 (ja) | 2007-02-16 | 2008-08-21 | Shimadzu Corporation | 上皮性卵巣癌の組織型識別マーカー、及びそれを用いた組織型に基づく上皮性卵巣癌の罹患の識別法 |
| TWI419901B (zh) * | 2007-03-23 | 2013-12-21 | Advpharma Inc | 利用腦衰蛋白反應媒介蛋白-１（ｃｒｍｐ-１）及其片段治療癌症之組合物及方法 |
| EP1983003A3 (en) * | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| WO2009075883A2 (en) | 2007-12-12 | 2009-06-18 | University Of Georgia Research Foundation, Inc. | Glycoprotein cancer biomarker |
| US8383360B2 (en) | 2009-08-14 | 2013-02-26 | The Regents Of The University Of California | Methods of diagnosing and treating autism |
| US20140134187A1 (en) * | 2012-06-25 | 2014-05-15 | The Johns Hopkins University | Therapeutic and diagnostic methods for autism spectrum disorders and other conditions |
| EP3314258B1 (en) | 2015-06-26 | 2023-11-15 | The Regents of the University of California | Antigenic peptides and uses thereof for diagnosing and treating autism |
-
2016
- 2016-06-23 EP EP16815305.4A patent/EP3314258B1/en active Active
- 2016-06-23 MX MX2017016329A patent/MX2017016329A/es unknown
- 2016-06-23 ES ES16815305T patent/ES2964981T3/es active Active
- 2016-06-23 JP JP2017567250A patent/JP6873060B2/ja active Active
- 2016-06-23 WO PCT/US2016/039029 patent/WO2016210137A1/en active Application Filing
- 2016-06-23 CA CA2989882A patent/CA2989882A1/en active Pending
- 2016-06-23 CN CN201680037784.2A patent/CN108184330B/zh active Active
- 2016-06-23 EP EP23204324.0A patent/EP4300101A3/en active Pending
- 2016-06-23 AU AU2016281649A patent/AU2016281649B2/en active Active
-
2017
- 2017-12-14 MX MX2022008215A patent/MX2022008215A/es unknown
- 2017-12-19 US US15/847,477 patent/US11098082B2/en active Active
-
2018
- 2018-10-31 HK HK18113905.7A patent/HK1254818A1/zh unknown
-
2021
- 2021-07-16 US US17/378,401 patent/US20210347824A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016281649B2 (en) | 2022-08-04 |
| EP3314258B1 (en) | 2023-11-15 |
| ES2964981T3 (es) | 2024-04-10 |
| US20180194807A1 (en) | 2018-07-12 |
| EP4300101A3 (en) | 2024-03-20 |
| US11098082B2 (en) | 2021-08-24 |
| CN108184330B (zh) | 2021-08-06 |
| HK1254818A1 (zh) | 2019-07-26 |
| MX2017016329A (es) | 2018-08-15 |
| CA2989882A1 (en) | 2016-12-29 |
| US20210347824A1 (en) | 2021-11-11 |
| EP3314258A1 (en) | 2018-05-02 |
| CN108184330A (zh) | 2018-06-19 |
| JP2018529630A (ja) | 2018-10-11 |
| EP3314258A4 (en) | 2019-04-10 |
| WO2016210137A1 (en) | 2016-12-29 |
| JP6873060B2 (ja) | 2021-05-19 |
| AU2016281649A1 (en) | 2018-01-18 |
| EP4300101A2 (en) | 2024-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008215A (es) | Peptidos antigenicos y usos de los mismos para diagnosticar y tratar el autismo. | |
| Becker et al. | Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia | |
| EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
| EA201991105A1 (ru) | Методы оценки риска с использованием общей и специфической неклеточной днк | |
| MX2021013681A (es) | Moleculas de union a lag-3 y metodos de uso de las mismas. | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| BR112017018821A2 (pt) | métodos para quantificação de níveis de insulina através de espectrometria de massa | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| BR112021024540A2 (pt) | Métodos para selecionar uma célula ou um vírus, determinar a sequência de um ácido nucleico, produzir uma célula que expressa um ácido nucleico e tratar um sujeito, célula imune selecionada e método para selecionar uma célula imune | |
| EA201891294A1 (ru) | Способ, в котором используется биспецифический белковый комплекс | |
| EA201790247A1 (ru) | Платформа для очистки биспецифичных антител | |
| MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
| JO3812B1 (ar) | أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1) | |
| MX2016002799A (es) | Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes. | |
| MY195045A (en) | Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer | |
| MX2016016742A (es) | Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). | |
| CY1121169T1 (el) | Αντισωμα που δεσμευει ενα γραμμικο επιτοπο ανθρωπινου ρ53 και διαγνωστικες εφαρμογες αυτου | |
| RU2015120601A (ru) | Эритроферрон и erfe-полипептиды и способы регуляции метаболизма железа | |
| EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
| WO2016198833A3 (en) | Methods for analysing a urine sample | |
| NZ729773A (en) | Biomarkers for disease progression in melanoma | |
| CY1121234T1 (el) | Μεθοδος για μη-επεμβατικη προγεννητικη ανιχνευση του ευπλοιδικου εμβυικου χρωμοσωματος απο το μητρικο αιμα |